Nye og genopdagede medikamenter til behandling af tuberkulose
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 179 KB, PDF-dokument
Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.
Bidragets oversatte titel | New and rediscovered treatments for tuberculosis |
---|---|
Originalsprog | Dansk |
Artikelnummer | V10210783 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 184 |
Udgave nummer | 10 |
Antal sider | 6 |
ISSN | 0041-5782 |
Status | Udgivet - 2022 |
Links
- https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-03/v10210783_web.pdf
Forlagets udgivne version
ID: 301455279